- Home
- REE vs NRXS Comparison
REE vs NRXS Comparison
Compare REE & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REE | NRXS |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 25.8M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | REE | NRXS |
|---|---|---|
| Price | $0.75 | $3.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.75 | $8.00 |
| AVG Volume (30 Days) | 112.1K | ★ 855.0K |
| Earning Date | 12-17-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $183,000.00 | ★ $3,362,320.00 |
| Revenue This Year | $327.73 | $31.05 |
| Revenue Next Year | $36,888.82 | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $0.53 | $1.33 |
| 52 Week High | $10.24 | $6.20 |
Technical Indicators
Market Signals| Indicator | REE | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 68.15 |
| Support Level | $0.65 | $2.63 |
| Resistance Level | $0.82 | $4.25 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 62.99 | 75.43 |
Price Performance
Historical ComparisonAbout REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).